Hengrui Pharmaceuticals Launched the GLP-1R/GIPR Double Agonist Head to Head Study on Phase III diabetes Mellitus

Recently, the ClinicalTrials website showed that Shengdi Pharmaceuticals, a subsidiary of Hengrui Pharmaceuticals, launched a multicenter, randomized, open label, parallel controlled phase III study (NCT06649344) of HRS9531, a GLP-1R/GIPR double agonist, to compare the efficacy and safety of HRS9531 and semaglutide in the treatment of type 2 diabetes patients with poor blood glucose control by metformin alone or in combination with sodium glucose co transporter 2 (SGLT2) inhibitors.

HRS9531 is a GLP-1/GIP dual receptor agonist independently developed by Hengrui Pharmaceutical, which activates the GIP receptor and GLP-1 receptor signaling pathway, enhances insulin secretion through dual effects on pancreatic beta cells, and has a stronger appetite suppressing effect on the activation of the two receptor signaling pathways in the brain. At the same time, GIP plays an important regulatory role in fat storage and adipose tissue function, manifested as increasing white adipose tissue blood flow perfusion and fat cell uptake of dietary triglycerides, improving long-term lipid storage and insulin resistance, thereby effectively controlling blood sugar and weight loss.

In May of this year, Hengrui Pharmaceutical launched the Phase III study (NCT06396429) of HRS9531 in the treatment of obesity, aiming to evaluate the effectiveness of HRS9531 in reducing weight in overweight or obese subjects compared to placebo after 48 weeks of treatment. It is estimated that the experiment will be completed in August 2025.